Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.

Experimental neurology - 1 Apr 2016

Garcia-Miralles Marta, Ooi Jolene, Ferrari Bardile Costanza, Tan Liang Juin, George Maya, Drum Chester L, Lin Rachel Yanping, Hayden Michael R, Pouladi Mahmoud A

Abstract excerpt

Abnormal monoamine oxidase A and B (MAO-A/B) activity and an imbalance in monoamine neurotransmitters have been suggested to underlie the pathobiology of depression, a major psychiatric symptom observed in patients with neurodegenerative diseases, such as Huntington disease (HD). Increased MAO-A/B activity has been observed in brain tissue from patients with HD and in human and rodent HD neural cells. Using the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Exploratory Behavior
Share to Hindlimb Suspension

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Huntingtin Protein

Share to Maze Learning

Share to Monoamine Oxidase

Share to Mood Disorders

Share to Neurotransmitter Agents

Share to Swimming

Source

Identifiers

PMID: 26825854
DOI: 10.1016/j.expneurol.2016.01.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.PMID 26825854Read ↗

Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 miceSemantic proximity Read ↗

Sirt1/FoxO1-Associated MAO-A Upregulation Promotes Depressive-Like Behavior in Transgenic Mice Expressing Human A53T α-Synuclein.Semantic proximity Read ↗

Dysfunctional striatal dopamine signaling in Huntington's diseaseSemantic proximity Read ↗

Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation.Semantic proximity Read ↗

Behavioral dysregulation and monoaminergic deficits precede memory impairments in human tau-overexpressing (htau) miceSemantic proximity Read ↗

Therapy development in Huntington disease: From current strategies to emerging opportunitiesSemantic proximity Read ↗

In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's DiseaseSemantic proximity Read ↗

A spontaneous point mutation produces monoamine oxidase A/B knock-out mice with greatly elevated monoamines and anxiety-like behavior.Semantic proximity Read ↗

Characterization of a novel mouse model of Dopamine Transporter Deficiency Syndrome and pharmacological therapeutic strategiesSemantic proximity Read ↗

A Tale of Two Maladies? Pathogenesis of Depression with and without the Huntington’s Disease Gene MutationSemantic proximity Read ↗

Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.Semantic proximity Read ↗

Motivational, proteostatic and transcriptional deficits precede synapse loss, gliosis and neurodegeneration in the B6. <i>Htt</i> <sup> <i>Q111/+</i> </sup> model of Huntington’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.